Joseph Yeboah1, Stefan Sillau2, Joseph C Delaney2, Michael J Blaha3, Erin D Michos3, Rebekah Young2, Waqas T Qureshi4, Robyn McClelland2, Gregory L Burke5, Bruce M Psaty6, David M Herrington4. 1. Heart and Vascular Center of Excellence, Wake Forest School of Medicine, Winston-Salem, NC. Electronic address: jyeboah@wakehealth.edu. 2. Department of Biostatistics, University Washington School of Medicine, Seattle, WA. 3. Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University School of Medicine, Baltimore MD. 4. Heart and Vascular Center of Excellence, Wake Forest School of Medicine, Winston-Salem, NC. 5. Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC. 6. Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology and Health Services, University of Washington, Seattle, WA; Group Health Research Unit, Group Health Cooperative, Seattle, WA.
Abstract
BACKGROUND: The impact of replacing the National Cholesterol Education Program (NCEP)/Adult Treatment Program (ATP) III cholesterol guidelines with the new 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for primary prevention of cardiovascular disease is unclear. METHODS: We used risk factor and 10-year clinical event rate data from MESA, combined with estimates of efficacy of moderate and high-intensity statin therapy from meta-analyses of statin primary prevention trials to estimate (a) the change in number of subjects eligible for drug therapy and (2) the anticipated reduction in atherosclerotic cardiovascular disease (ASCVD) events and increment in type 2 diabetes mellitus (T2DM) associated with the change in cholesterol guidelines. RESULTS: Of the 6,814 MESA participants, 5,437 were not on statins at baseline and had complete data for analysis (mean age 61.4±10.3). Using the NCEP/ATP III guidelines, 1,334 (24.5%) would have been eligible for statin therapy compared with 3,015 (55.5%) under the new ACC/AHA guidelines. Among the subset of newly eligible, 127/1,742 (7.3%) had an ASCVD event during 10years of follow-up. Assuming 10years of moderate-intensity statin therapy, the estimated absolute reduction in ASCVD events for the newly eligible group was 2.06% (number needed to treat [NNT] 48.6) and the estimated absolute increase in T2DM was 0.90% (number needed to harm [NNH] 110.7). Assuming 10years of high-intensity statin therapy, the corresponding estimates for reductions in ASCVD and increases in T2DM were as follows: ASCVD 2.70% (NNT 37.5) and T2DM 2.60% (NNH 38.6). The estimated effects of moderate-intensity statins on 10-year risk for ASCVD and T2DM in participants eligible for statins under the NCEP/ATP III were as follows: 3.20% (NNT 31.5) and 1.06% (NNH 94.2), respectively. CONCLUSION: Substituting the NCEP/ATP III cholesterol guidelines with the 2013 ACC/AHA cholesterol guidelines in MESA more than doubled the number of participants eligible for statin therapy. If the new ACC/AHA cholesterol guidelines are adopted and extend the primary prevention population eligible for treatment, the risk-benefit profile is much better for moderate-intensity than high-intensity statin treatment.
BACKGROUND: The impact of replacing the National Cholesterol Education Program (NCEP)/Adult Treatment Program (ATP) III cholesterol guidelines with the new 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for primary prevention of cardiovascular disease is unclear. METHODS: We used risk factor and 10-year clinical event rate data from MESA, combined with estimates of efficacy of moderate and high-intensity statin therapy from meta-analyses of statin primary prevention trials to estimate (a) the change in number of subjects eligible for drug therapy and (2) the anticipated reduction in atherosclerotic cardiovascular disease (ASCVD) events and increment in type 2 diabetes mellitus (T2DM) associated with the change in cholesterol guidelines. RESULTS: Of the 6,814 MESAparticipants, 5,437 were not on statins at baseline and had complete data for analysis (mean age 61.4±10.3). Using the NCEP/ATP III guidelines, 1,334 (24.5%) would have been eligible for statin therapy compared with 3,015 (55.5%) under the new ACC/AHA guidelines. Among the subset of newly eligible, 127/1,742 (7.3%) had an ASCVD event during 10years of follow-up. Assuming 10years of moderate-intensity statin therapy, the estimated absolute reduction in ASCVD events for the newly eligible group was 2.06% (number needed to treat [NNT] 48.6) and the estimated absolute increase in T2DM was 0.90% (number needed to harm [NNH] 110.7). Assuming 10years of high-intensity statin therapy, the corresponding estimates for reductions in ASCVD and increases in T2DM were as follows: ASCVD 2.70% (NNT 37.5) and T2DM 2.60% (NNH 38.6). The estimated effects of moderate-intensity statins on 10-year risk for ASCVD and T2DM in participants eligible for statins under the NCEP/ATP III were as follows: 3.20% (NNT 31.5) and 1.06% (NNH 94.2), respectively. CONCLUSION: Substituting the NCEP/ATP IIIcholesterol guidelines with the 2013 ACC/AHA cholesterol guidelines in MESA more than doubled the number of participants eligible for statin therapy. If the new ACC/AHA cholesterol guidelines are adopted and extend the primary prevention population eligible for treatment, the risk-benefit profile is much better for moderate-intensity than high-intensity statin treatment.
Authors: David Preiss; Sreenivasa Rao Kondapally Seshasai; Paul Welsh; Sabina A Murphy; Jennifer E Ho; David D Waters; David A DeMicco; Philip Barter; Christopher P Cannon; Marc S Sabatine; Eugene Braunwald; John J P Kastelein; James A de Lemos; Michael A Blazing; Terje R Pedersen; Matti J Tikkanen; Naveed Sattar; Kausik K Ray Journal: JAMA Date: 2011-06-22 Impact factor: 56.272
Authors: Naveed Sattar; David Preiss; Heather M Murray; Paul Welsh; Brendan M Buckley; Anton J M de Craen; Sreenivasa Rao Kondapally Seshasai; John J McMurray; Dilys J Freeman; J Wouter Jukema; Peter W Macfarlane; Chris J Packard; David J Stott; Rudi G Westendorp; James Shepherd; Barry R Davis; Sara L Pressel; Roberto Marchioli; Rosa Maria Marfisi; Aldo P Maggioni; Luigi Tavazzi; Gianni Tognoni; John Kjekshus; Terje R Pedersen; Thomas J Cook; Antonio M Gotto; Michael B Clearfield; John R Downs; Haruo Nakamura; Yasuo Ohashi; Kyoichi Mizuno; Kausik K Ray; Ian Ford Journal: Lancet Date: 2010-02-16 Impact factor: 79.321
Authors: Paul M Ridker; Eleanor Danielson; Francisco A H Fonseca; Jacques Genest; Antonio M Gotto; John J P Kastelein; Wolfgang Koenig; Peter Libby; Alberto J Lorenzatti; Jean G MacFadyen; Børge G Nordestgaard; James Shepherd; James T Willerson; Robert J Glynn Journal: N Engl J Med Date: 2008-11-09 Impact factor: 91.245
Authors: Swapnil N Rajpathak; Dharam J Kumbhani; Jill Crandall; Nir Barzilai; Michael Alderman; Paul M Ridker Journal: Diabetes Care Date: 2009-10 Impact factor: 19.112
Authors: Fiona Taylor; Mark D Huffman; Ana Filipa Macedo; Theresa H M Moore; Margaret Burke; George Davey Smith; Kirsten Ward; Shah Ebrahim Journal: Cochrane Database Syst Rev Date: 2013-01-31
Authors: Yashashwi Pokharel; Fengming Tang; Philip G Jones; Vijay Nambi; Vera A Bittner; Ravi S Hira; Khurram Nasir; Paul S Chan; Thomas M Maddox; William J Oetgen; Paul A Heidenreich; William B Borden; John A Spertus; Laura A Petersen; Christie M Ballantyne; Salim S Virani Journal: JAMA Cardiol Date: 2017-04-01 Impact factor: 14.676
Authors: Heather M Ochs-Balcom; Ly Minh Nguyen; Changxing Ma; Paul J Isackson; Jasmine A Luzum; Joseph P Kitzmiller; Mark Tarnopolsky; Michael Weisman; Lisa Christopher-Stine; Wendy Peltier; Robert L Wortmann; Georgirene D Vladutiu Journal: Muscle Nerve Date: 2019-01-11 Impact factor: 3.217
Authors: Yashashwi Pokharel; Lynne Steinberg; Winston Chan; Julia M Akeroyd; Peter H Jones; Vijay Nambi; Khurram Nasir; Laura Petersen; Christie M Ballantyne; Salim S Virani Journal: Atherosclerosis Date: 2016-01-06 Impact factor: 5.162
Authors: Ashley Chorath; Younhee Choi; Evrim B Turkbey; Mark A Ahlman; Christopher T Sibley; Songtao Liu; David A Bluemke; Veit Sandfort Journal: Radiol Cardiothorac Imaging Date: 2020-02-27
Authors: Waqas T Qureshi; Robert C Kaplan; Katrina Swett; Gregory Burke; Martha Daviglus; Molly Jung; Gregory A Talavera; Diana A Chirinos; Samantha A Reina; Sonia Davis; Carlos J Rodriguez Journal: J Am Heart Assoc Date: 2017-05-11 Impact factor: 5.501
Authors: Nonanzit Pérez-Hernández; Gilberto Vargas-Alarcón; Rosalinda Posadas-Sánchez; Nancy Martínez-Rodríguez; Carlos Alfonso Tovilla-Zárate; Adrián Asael Rodríguez-Cortés; Oscar Pérez-Méndez; Ruben Blachman-Braun; José Manuel Rodríguez-Pérez Journal: Int J Environ Res Public Health Date: 2016-08-09 Impact factor: 3.390